TCV Trust & Wealth Management 13F: Exits CVS Health (CVS) Stake
TCV Trust & Wealth Management has sold all 5,775 shares of CVS Health Corporation as reported in its latest 13F filing.
Reviewed by automated data checks against the source filing. How we make and check alerts
TCV Trust & Wealth Management sold its entire stake of 5,775 shares in CVS Health Corporation ($CVS), according to a 13F filing with the SEC dated October 16, 2026.
Find the original: TCV Trust & Wealth Management 13F filings on SEC EDGAR
CVS
CVS Health Corporation
Key Points
- TCV Trust & Wealth Management cut its entire position in CVS Health, selling 5,775 shares with a total value of $0 as it now holds no shares in the company.
- CVS Health recently traded around $92.83, which is below its mean price target of $115.48 and 16.1% below its 52-week high of $110.68.
- Analysts maintain a strong buy consensus on CVS, with UBS maintaining a $126 price target as of August 6, 2026.
Get $CVS trade alerts by text
We text you when insiders, Congress or big funds trade $CVS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated CVS Health Corporation alert may contain errors. Disclosures
TCV Trust & Wealth Management sold out of its position in CVS Health Corporation (NYSE: CVS), according to a filing on October 16, 2026. The firm reduced its stake by 5,775 shares, bringing its total to zero. This cut reflects a 100% decrease in ownership.
Other Institutional Activity in CVS Health
Blackrock Inc. reduced its holdings by 2,694,646 shares, ending with 123,223,409 shares worth about $11.4 billion. Capital World Investors also cut its stake, down 2,294,211 shares to 74,951,955 shares valued at approximately $6.9 billion. Meanwhile, Vanguard Capital Management LLC added 661,233 shares, increasing its total to 83,315,369 shares valued at about $7.7 billion. State Street Corporation grew its position by 961,023 shares, totaling 60,283,408 shares worth approximately $5.6 billion.
CVS Health Corporation Stock Up 2.7%
CVS Health shares recently traded around $92.83, which is above both its 50-day moving average of $91.80 and its 200-day moving average of $88.12. However, the stock is 16.1% below its 52-week high of $110.68. The recent price is also 19.6% below the mean price target set by analysts, which is $115.48.
Recent Earnings
For the trailing twelve months, CVS Health reported revenue of approximately $412.6 billion and earnings per share of $3.80. The next earnings report is scheduled for November 4, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
11 analysts raised price targets.
-
EPS & revenue
EPS beat estimates by 15.8%. Revenue beat estimates by 4.6%.
-
Profit surprise
EBITDA beat by 15 percent. Operating income beat by 4 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
11 target raises.
-
Earnings quality
Operating margin up 1.1 points. Positive free cash flow.
Earnings Call Summary
CVS delivered a strong first quarter with $100.4 billion in revenue, up 6 percent year over year, and earnings per share of $2.57, beating consensus by 36 cents. The Aetna health insurance business showed major improvement with operating income up 1 billion dollars year over year and a better medical benefit ratio. Pharmacy sales grew 3 percent at existing stores driven by strong prescription volume increases. Management is focused on affordability, reducing friction in the health system, and launching a new consumer app called Health100 powered by artificial intelligence.
Guidance CVS raised full year earnings guidance to $7.30 to $7.50 per share, up from $7.00 to $7.20. They expect at least $405 billion in revenue for the year. Operating cash flow guidance improved to at least $9.5 billion.
Good report. The company beat and showed some forward improvement, with a few meaningful caveats.
Insider Buying and Selling at CVS Health Corporation
Tilak Mandadi, an officer at CVS, sold 69,551 shares at an average price of $89.58 on May 8, 2026, for a total value of about $6.2 million. Additionally, Director Larry Robbins sold 3,372,000 shares on May 21, 2026, valued at roughly $317.5 million.
Analysts Set New Price Targets
On August 6, 2026, UBS maintained a Buy rating for CVS Health with a price target of $126. JP Morgan also maintained an Overweight rating with a target of $118 on August 12, 2026. According to the consensus from 25 analysts, CVS has a strong buy recommendation, with a mean price target of $115.48.
About CVS Health
CVS Health Corporation offers a variety of health solutions across the United States, including health insurance products and pharmacy services. The company operates in the healthcare plans industry and provides services that range from medical and pharmacy plans to Medicaid healthcare management services.
Bottom Line
Investors should monitor CVS Health's upcoming earnings report on November 4, 2026, for insights into its financial performance. The recent actions of TCV Trust & Wealth Management show a significant change in institutional sentiment, although the broader analyst consensus remains positive despite the stock's recent price performance. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.
Related Filing Alerts
Source: TCV Trust & Wealth Management's 13F filing on $CVS (Oct 16, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: TCV Trust & Wealth Management 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts